Immatics biotechnologies
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 31.3m | 34.8m | 173m | 54.0m | 72.3m | 61.1m | 54.2m |
% growth | 69 % | 11 % | 397 % | (69 %) | 34 % | (15 %) | (11 %) |
EBITDA | (64.4m) | (75.4m) | 46.3m | (80.6m) | (102m) | (143m) | (221m) |
% EBITDA margin | (206 %) | (217 %) | 27 % | (149 %) | (141 %) | (234 %) | (409 %) |
Profit | (229m) | (93.3m) | 37.5m | (97.0m) | (88.6m) | (131m) | (162m) |
% profit margin | (733 %) | (268 %) | 22 % | (180 %) | (123 %) | (214 %) | (299 %) |
EV / revenue | 12.7x | 18.6x | 1.5x | 7.5x | 8.3x | 17.0x | 19.2x |
EV / EBITDA | -6.1x | -8.6x | 5.7x | -5.0x | -5.9x | -7.3x | -4.7x |
R&D budget | 67.1m | 87.6m | 107m | 119m | - | - | - |
R&D % of revenue | 215 % | 252 % | 62 % | 220 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$7.8m | Series A | ||
$40.0m | Series B | ||
$54.0m | Series C | ||
$12.0m | Series D | ||
$22.0m | Series D | ||
$40.3m | Grant | ||
$30.0m | Series E | ||
* | $58.0m | Series E | |
$75.0m | Series F | ||
$149m Valuation: $288m 14.2x EV/LTM Revenues -9.2x EV/LTM EBITDA | SPAC IPO | ||
$104m Valuation: $288m 14.2x EV/LTM Revenues -9.2x EV/LTM EBITDA | SPAC Private Placement | ||
* | $110m | Post IPO Equity | |
* | $35.0m | Private Placement VC | |
Total Funding | €435m |
Related Content
Recent News about Immatics biotechnologies
EditImmatics is a biotechnology company specializing in the development of advanced cancer immunotherapies. The company focuses on discovering true targets for cancer treatment and developing T cell receptors (TCRs) to enable a robust and specific T cell response against these targets. Immatics operates in the biopharmaceutical market, primarily serving patients battling various forms of cancer. The business model includes the development of proprietary Adoptive Cell Therapies and TCR Bispecifics, as well as strategic partnerships with global pharmaceutical leaders. Revenue is generated through a combination of product sales, licensing agreements, and collaborative research and development projects. The company's innovative approach aims to unlock new treatment avenues and improve patient outcomes in the fight against cancer.
Keywords: cancer immunotherapy, T cell receptors, Adoptive Cell Therapies, TCR Bispecifics, biotechnology, pharmaceutical partnerships, patient-specific treatments, oncology, biopharmaceutical market, innovative therapies.